Investigations of Reproductive Cancers in Women

NCT06527157 — Recruiting, 4500 participants, PinkDx, Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

PROspective ACcrual To Investigate reprOductive Cancers in womeN

RegistryNCT06527157, acronym PROACTION:
StatusRecruiting
Study typeObservational
Enrollment4500 (Estimated)
SponsorPinkDx, Inc. (Industry)
ConditionsUterine Cancer
Datesstart 2024-07-30, primary completion 2026-10-30 (estimated), completion 2031-11-15 (estimated), first posted 2024-07-30, last updated 2026-08-17
Locations16 sites in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Uterine Cancer

-Summary

The goal of this study is to create a non-invasive diagnostic test to rule out gynecological cancer in females aged 45 and older with abnormal uterine or postmenopausal bleeding.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Benignsample collection from females with benign causes of AUB/PMB
Malignantsample collection from females with malignant causes of AUB/PMB

+Outcome measures

Primary outcomes

  • Sensitivity [12 months]: ability to detect cancer

Secondary outcomes

  • Specificity [12 months]: ability to identify benign cases

+Eligibility

Sex: Female, ages: 45 Years to 100 Years

Inclusion Criteria:

1. Evidence of a personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study.
2. Willing and able to comply with scheduled visits, study plan, and other procedures.
3. Expected to be available for the duration of the study and can be contacted by telephone during study participation.
4. Females aged 45 and older (with roughly 80% of enrolled subjects over the age of 50).
5. Presence of uterus.
6. AUB or PMB being worked up to diagnose the cause of the bleeding

Exclusion Criteria:

1. Investigator site staff members directly involved in the conduct of the study and their family members or subjects who are PinkDx, Inc. employees or their family members.
2. Other medical or psychiatric conditions that would increase the risk of study participation in the judgement of the Investigator.
3. Women who have had a hysterectomy.
4. Women with a known history of endometrial cancer or uterine sarcoma.
5. Women who have received prior treatment for endometrial cancer.
6. Inability or unwillingness to sign informed consent.
7. Clinical suspicion of pregnancy.
8. Women who have used a tampon within 7 days of sample collection.

+Locations (16)

FacilityCityCountryStatus
University of Alabama, BirminghamBirmingham, AlabamaUnited StatesRecruiting
Sutter HealthSan Carlos, CaliforniaUnited StatesRecruiting
Advent Health OrlandoOrlando, FloridaUnited StatesRecruiting
Ob-Gyne Associates of Lake Forest, LtdLake Forest, IllinoisUnited StatesActive not recruiting
Indiana University, Eskenazi HealthIndianapolis, IndianaUnited StatesRecruiting
Mayo ClinicRochester, MinnesotaUnited StatesActive not recruiting
Washington University School of MedicineSt Louis, MissouriUnited StatesRecruiting
Columbia UniversityNew York, New YorkUnited StatesRecruiting
Summa HealthAkron, OhioUnited StatesRecruiting
The Ohio State UniversityColumbus, OhioUnited StatesRecruiting
Avera Research InstituteSioux Falls, South DakotaUnited StatesActive not recruiting
University of Tennessee Health Science CenterMemphis, TennesseeUnited StatesRecruiting
Meharry Medical CollegeNashville, TennesseeUnited StatesRecruiting
Baylor College of Medicine/Texas Children's HospitalHouston, TexasUnited StatesRecruiting
Houston MethodistHouston, TexasUnited StatesRecruiting
University of Texas Health Science Center at San AntonioSan Antonio, TexasUnited StatesRecruiting

+Investigators